Collection |

Cancer at Nature Research

The Nature Research editors who handle cancer primary research, methods, protocols and reviews bring you the latest articles, covering all aspects from disease mechanisms to therapeutic approaches. Collected here you will also find specially curated content, such as collections, focus issues and animations, all ready to be used in presentations and educational materials. You can also find out about the editors handling cancer contents, and the journals at Nature Research that publish articles on this topic and how to submit to them.

Sign up to the e-alert to receive highlights direct to your inbox.

Research Articles

  • Nature | Letter

    An immunoprecipitation-based protocol is developed to analyse DNA methylation in small quantities of circulating cell-free DNA, and can detect and classify cancers in plasma samples from several tumour types.

    • Shu Yi Shen
    • , Rajat Singhania
    • , Gordon Fehringer
    • , Ankur Chakravarthy
    • , Michael H. A. Roehrl
    • , Dianne Chadwick
    • , Philip C. Zuzarte
    • , Ayelet Borgida
    • , Ting Ting Wang
    • , Tiantian Li
    • , Olena Kis
    • , Zhen Zhao
    • , Anna Spreafico
    • , Tiago da Silva Medina
    • , Yadon Wang
    • , David Roulois
    • , Ilias Ettayebi
    • , Zhuo Chen
    • , Signy Chow
    • , Tracy Murphy
    • , Andrea Arruda
    • , Grainne M. O’Kane
    • , Jessica Liu
    • , Mark Mansour
    • , John D. McPherson
    • , Catherine O’Brien
    • , Natasha Leighl
    • , Philippe L. Bedard
    • , Neil Fleshner
    • , Geoffrey Liu
    • , Mark D. Minden
    • , Steven Gallinger
    • , Anna Goldenberg
    • , Trevor J. Pugh
    • , Michael M. Hoffman
    • , Scott V. Bratman
    • , Rayjean J. Hung
    •  &  Daniel D. De Carvalho
  • Nature Communications | Article | open

    In vivo studies on the regulation of the epithelial-mesenchymal transition (EMT) within a physiological context are lacking. Here it is shown that miR-200 ablation in the Rip-Tag2 insulinoma mouse model induces beta-cell dedifferentiation, EMT and tumor invasion, and that disruption of Zeb1 regulation by miR-200c is sufficient to drive EMT.

    • Alexandra C. Title
    • , Sue-Jean Hong
    • , Nuno D. Pires
    • , Lynn Hasenöhrl
    • , Svenja Godbersen
    • , Nadine Stokar-Regenscheit
    • , David P. Bartel
    •  &  Markus Stoffel
  • Nature Communications | Article | open

    Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lung cancer prior to treatment with immunotherapy and show it correlates with response.

    • A. N. Niemeijer
    • , D. Leung
    • , M. C. Huisman
    • , I. Bahce
    • , O. S. Hoekstra
    • , G. A. M. S. van Dongen
    • , R. Boellaard
    • , S. Du
    • , W. Hayes
    • , R. Smith
    • , A. D. Windhorst
    • , N. H. Hendrikse
    • , A. Poot
    • , D. J. Vugts
    • , E. Thunnissen
    • , P. Morin
    • , D. Lipovsek
    • , D. J. Donnelly
    • , S. J. Bonacorsi
    • , L. M. Velasquez
    • , T. D. de Gruijl
    • , E. F. Smit
    •  &  A. J. de Langen
  • Nature Communications | Article | open

    Identification of response biomarkers is a key step towards the development of personalised care. Here, Jayson et al. identify plasma Tie2 as a biomarker for the response of the tumor vasculature to anti-angiogenics in patients with metastatic colorectal cancer, suggesting that monitoring Tie2 levels may help guide therapy in the clinics.

    • Gordon C. Jayson
    • , Cong Zhou
    • , Alison Backen
    • , Laura Horsley
    • , Kalena Marti-Marti
    • , Danielle Shaw
    • , Nerissa Mescallado
    • , Andrew Clamp
    • , Mark P. Saunders
    • , Juan W. Valle
    • , Saifee Mullamitha
    • , Mike Braun
    • , Jurjees Hasan
    • , Delyth McEntee
    • , Kathryn Simpson
    • , Ross A. Little
    • , Yvonne Watson
    • , Susan Cheung
    • , Caleb Roberts
    • , Linda Ashcroft
    • , Prakash Manoharan
    • , Stefan J. Scherer
    • , Olivia del Puerto
    • , Alan Jackson
    • , James P. B. O’Connor
    • , Geoff J. M. Parker
    •  &  Caroline Dive
  • Nature Communications | Article | open

    Acquired resistance to targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. Here, the authors show how the acquired EGFRG724S mutation induces resistance to third-generation EGFR inhibitors and why the mutant kinase remains susceptible to second-generation inhibitors.

    • Jana Fassunke
    • , Fabienne Müller
    • , Marina Keul
    • , Sebastian Michels
    • , Marcel A. Dammert
    • , Anna Schmitt
    • , Dennis Plenker
    • , Jonas Lategahn
    • , Carina Heydt
    • , Johannes Brägelmann
    • , Hannah L. Tumbrink
    • , Yannic Alber
    • , Sebastian Klein
    • , Alena Heimsoeth
    • , Ilona Dahmen
    • , Rieke N. Fischer
    • , Matthias Scheffler
    • , Michaela A. Ihle
    • , Vanessa Priesner
    • , Andreas H. Scheel
    • , Svenja Wagener
    • , Anna Kron
    • , Konrad Frank
    • , Katia Garbert
    • , Thorsten Persigehl
    • , Michael Püsken
    • , Stefan Haneder
    • , Bernhard Schaaf
    • , Ernst Rodermann
    • , Walburga Engel-Riedel
    • , Enriqueta Felip
    • , Egbert F. Smit
    • , Sabine Merkelbach-Bruse
    • , H. Christian Reinhardt
    • , Stefan M. Kast
    • , Jürgen Wolf
    • , Daniel Rauh
    • , Reinhard Büttner
    •  &  Martin L. Sos

Reviews

  • Nature Reviews Cancer | Review Article

    Therapy with live tumour-targeting bacteria represents a unique opportunity to address the limitations associated with molecularly targeted therapies and immunotherapies. In this Review, Zhou et al. discuss the benefits and challenges of this approach and outline advances in the engineering of bacteria, which have the potential to improve safety and efficacy.

    • Shibin Zhou
    • , Claudia Gravekamp
    • , David Bermudes
    •  &  Ke Liu
  • Nature Reviews Clinical Oncology | Perspective

    Many clinical trials are testing the safety and/or efficacy of combining radiotherapy with immunotherapy, nearly all using a single-site irradiation (or ‘abscopal’) approach, but emerging evidence suggests that this approach likely produces suboptimal results. The authors of this Perspective provide a biological rationale supporting the abandonment of the abscopal approach, and instead advocate exploring comprehensive irradiation of multiple/all lesions.

    • Eric D. Brooks
    •  &  Joe Y. Chang
  • Nature Medicine | Perspective

    A neoadjuvant approach using combined anti-CTLA4/anti-PD1 treatment prior to lymph node surgery is evaluated in two phase I trials of later stage melanoma finding this a therapeutic angle worth pursuing.

    • Caroline Robert

News & Commentary